» Articles » PMID: 19324130

Renal Function and Outcome After Continuous Flow Left Ventricular Assist Device Implantation

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2009 Mar 28
PMID 19324130
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Renal dysfunction as a risk factor with the use of left ventricular assist devices (LVAD) is controversial. We determined the effect of renal function on outcomes after continuous flow LVAD implantation.

Methods: Eighty-six patients with advanced heart failure undergoing continuous flow LVAD implantation as bridge to transplantation from November 1998 to July 2007 were retrospectively analyzed. Renal function was assessed using the Modification of Diet in Renal Disease study-derived glomerular filtration rates (GFR [mL x min(-1) x 1.73 m(-2)]). Patients were categorized into two groups based on pre-LVAD GFR: those with normal renal function (GFR > 60, n = 46), and those with renal dysfunction (GFR < 60, n = 40).

Results: Post-LVAD survival at 1, 3, and 6 months for GFR greater than 60 was 91.3%, 79.9%, 72.6%, respectively, and for GFR less than 60, it was 92.5%, 66.5%, 47.9%, respectively (p = 0.038). Bridge-to-transplant rate was lower for GFR less than 60 than for GFR greater than 60 (40.0% versus 63.0%, p = 0.033). For GFR less than 60, GFR improved on LVAD support: implant to month 6, 41.7 +/- 11.5 to 62.7 +/- 25.0 (p = 0.021). Post-LVAD survival was improved in GFR less than 60 patients who after LVAD implantation recovered renal function to GFR greater than 60 (p < 0.001). Patients with post-LVAD renal failure had significantly lower post-LVAD survival regardless of pre-LVAD renal function (p < 0.001).

Conclusions: Patients with renal dysfunction have poorer outcomes after continuous flow LVAD implantation. However, renal function improves after LVAD implantation and is associated with improved survival. Our data underscore the importance of end-organ function in patient selection for LVAD therapy.

Citing Articles

Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices.

Antonopoulos M, Bonios M, Dimopoulos S, Leontiadis E, Gouziouta A, Kogerakis N J Cardiovasc Dev Dis. 2024; 11(2).

PMID: 38392275 PMC: 10888700. DOI: 10.3390/jcdd11020061.


Improvement of persistent anuria in severe myocardial infarction: the potential role of Impella 5.5 as a bridge to decision.

Suzuki T, Sugiura R BMJ Case Rep. 2023; 16(12).

PMID: 38129092 DOI: 10.1136/bcr-2023-255462.


Long-term kidney outcomes in pediatric continuous-flow ventricular assist device patients.

Idrovo A, Hollander S, Neumayr T, Bell C, Munoz G, Choudhry S Pediatr Nephrol. 2023; 39(4):1289-1300.

PMID: 37971519 DOI: 10.1007/s00467-023-06190-8.


The impact of preoperative kidney replacement therapy on kidney outcome and survival in patients with left ventricular assist device.

Jeon H, Jeon J, Lee K, Kim D, Cho Y, Lee J Ren Fail. 2023; 45(1):2157285.

PMID: 36763000 PMC: 9930763. DOI: 10.1080/0886022X.2022.2157285.


Long-Term Changes in Estimated Glomerular Filtration Rate in Left Ventricular Assist Device Recipients: A Longitudinal Joint Model Analysis.

Roehm B, Hedayati S, Vest A, Gulati G, Miao J, Tighiouart H J Am Heart Assoc. 2023; 12(3):e025993.

PMID: 36734339 PMC: 9973635. DOI: 10.1161/JAHA.122.025993.